A primary challenge in peptide research is the rapid degradation and clearance of synthetic peptides. Endogenous enzymes and renal filtration frequently reduce peptide half-life to only minutes, necessitating repeated administration to achieve sustained biological effects in animal models.
CJC-1295, a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), is notable for its capacity to stimulate pulsatile growth hormone release. Its primary biochemical innovation is the integration of a Drug Affinity Complex (DAC) within its molecular structure.
This article examines the science underlying DAC technology, its role in facilitating plasma protein binding, and its impact on the pharmacokinetic profile of CJC-1295 in research settings.
The Nomenclature Nuance: CJC-1295 vs. Mod GRF 1-29
Before discussing the mechanics of the Drug Affinity Complex, it is important to clarify a common nomenclature issue within the research community.
Products are frequently labeled as “CJC-1295 without DAC.” However, a GHRH analogue lacking the DAC component is scientifically classified as Modified GRF 1-29. Modified GRF 1-29 exhibits a half-life of approximately 30 minutes, which is a notable improvement over endogenous GHRH, though still relatively brief.
Authentic CJC-1295 includes the DAC, and this molecular addition extends the peptide’s half-life from minutes to approximately 6 to 8 days.
Decoding the Drug Affinity Complex (DAC)
The Drug Affinity Complex is a bioconjugation technology developed to protect peptides from enzymatic cleavage, particularly by dipeptidyl peptidase IV (DPP-IV), and to reduce renal clearance. This protection is achieved through a targeted chemical reaction that occurs when the peptide enters the test subject’s bloodstream.
The Mechanism of Covalent Binding
The DAC component incorporated into the CJC-1295 peptide chain is a reactive chemical group, specifically a maleimidopropionic acid linker. The following outlines the process by which this modification influences plasma protein binding:
- Upon introduction into a biological system, the maleimido group of CJC-1295 targets proteins circulating in the blood plasma.
- The primary target is serum albumin, the most abundant protein in blood plasma. Albumin functions as a major transport vehicle for hormones, fatty acids, and exogenous compounds.
- The maleimido group exhibits high specificity, reacting almost exclusively with free thiol (sulfhydryl) groups. In serum albumin, the principal free thiol group is located at the Cysteine-34 (Cys34) amino acid residue.
- The linker forms a stable, covalent bond with Cys34, resulting in the peptide being physically attached to the albumin molecule.
The Impact on Duration and Pharmacokinetics
Attachment to serum albumin significantly alters the pharmacokinetic profile of CJC-1295. This bioconjugation provides two primary protective advantages:
- Albumin, a large protein of approximately 66 kDa, acts as a physical shield. The attached CJC-1295 peptide is protected from proteolytic enzymes such as DPP-IV, which are unable to access the cleavage sites on the peptide chain.
- The kidneys rapidly filter small molecules and peptides. However, albumin is too large to pass through the renal glomerulus. As CJC-1295 is permanently attached to albumin, it remains in systemic circulation for the duration of the albumin molecule’s presence.
Sustained Release in Research Models
This extended duration of action enables new methodological approaches in laboratory research. Given that the half-life of albumin in humans and many mammals spans several weeks, the half-life of CJC-1295 with DAC is extended to approximately 8 days.
A single administration in an animal model can stimulate the anterior pituitary to secrete growth hormone in a natural, pulsatile manner for over a week. This sustained elevation enables researchers to investigate the long-term metabolic, cellular, and physiological effects of increased IGF-1 and GH levels without the confounding variables associated with multiple daily injections.
Summary
The incorporation of a Drug Affinity Complex exemplifies advanced peptide engineering. By utilizing endogenous circulating albumin as a protective carrier, CJC-1295 with DAC addresses the traditional limitations of peptide instability. For researchers studying neuroendocrine function, cellular regeneration, and metabolic regulation, it offers a stable, long-acting tool for collecting accurate longitudinal data.
Advance Your Laboratory Research with Elite Miami Peptides
Precision in laboratory research depends on the purity of compounds. Elite Miami Peptides supplies USA-synthesized, rigorously tested, research-grade peptides to support accurate and reproducible data.
The catalog includes ultra-pure CJC-1295 with DAC and other advanced peptide formulations suitable for laboratory studies.
Disclaimer: The following information is for educational and informational purposes only. Elite Miami Peptides supplies products exclusively for in vitro and laboratory research use. They are not intended for human consumption, diagnostic, therapeutic, or preventative purposes.